NCT07067788 B.Brilliant Revelation Comparision Study
| NCT ID | NCT07067788 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Breast Cancer Screening |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-12-15 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices
Eligibility Criteria
Inclusion Criteria 1. Participants will be ≥ 18 years of age. 2. Participants will be females (sex assigned at birth). 3. Participants will be presenting for clinical diagnostic mammography with suspicious calcifications or calcifications associated with other lesion types 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria 1. Females who are breast-feeding will not be eligible for this study 2. Pregnant women will not be included. All females of childbearing potential must attest that they are not pregnant. 3. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. 4. Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Contact & Investigator
Namaijah Faison Clinical Research Coordinator
✉ Namaijah.Faison@pennmedicine.upenn.edu📞 215-432-5000
Brian S Englander, MD
PRINCIPAL INVESTIGATOR
Pennsylvania Hospital
Frequently Asked Questions
Who can join the NCT07067788 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07067788 currently recruiting?
Yes, NCT07067788 is actively recruiting participants. Contact the research team at Namaijah.Faison@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07067788 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07067788 clinical trial?
NCT07067788 is sponsored by University of Pennsylvania. The principal investigator is Brian S Englander, MD at Pennsylvania Hospital. The trial plans to enroll 100 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.